A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated With Orkambi
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs P 1037 (Primary) ; Ivacaftor; Lumacaftor
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 09 Aug 2017 Planned primary completion date changed from 25 Jul 2017 to 22 Aug 2017.
- 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Jun 2017 Planned End Date changed from 1 Jun 2017 to 22 Aug 2017.